Results 61 to 70 of about 45,340 (263)

Development and evaluation of a maturity assessment tool for integrating building information modelling into operations and maintenance phase of buildings

Developments in the Built Environment
The emergence of advanced digital tools such as building information modelling (BIM) has transformed the concept of building management in the construction sector.
Dania K. Abideen, Akilu Yunusa-Kaltungo, Clara Cheung, Patrick Manu   +3 more
doaj   +1 more source

The structure of the community according to the data from the Bronze Age burial ground of Bestamak [PDF]

Вестник археологии, антропологии и этнографии
The Bestamak burial ground is located in the center of the Turgai trough, which connects the West Siberian and Turanian plains. The data obtained during its study suggests that of all prehistoric sites, closest to Bestamak is the well-known Sintashta ...
Kalieva S.S., Logvin A.V., Logvin V.N., Shevnina I.V.   +3 more
doaj   +1 more source

Probing Machine Learning Interatomic Potentials on Ion Transport Properties

Advanced Intelligent Discovery, EarlyView.
We perform a systematic benchmark of six state‐of‐the‐art universal machine learning interatomic potentials on their ability to predict ion transport properties in lithium‐ and sodium‐based superionic conductors relevant to all‐solid‐state batteries.
Ogheneyoma Aghoghovbia, Ming Hu, Adji Bousso Dieng   +2 more
wiley   +1 more source

Phylogenomic insights into the genus Tulipa (Liliaceae): Taxonomy, evolution, and biogeography

American Journal of Botany, EarlyView.
Abstract Premise Tulips are one of the best‐known geophytes, but their taxonomy remains convoluted and their evolutionary history poorly understood. Here, we used plastid genomes to identify some issues with current classification, understand the diversification history of the genus, and identify potential species linked to historical cultivation ...
Brett Wilson, Maarten J. M. Christenhusz, Nathanael Walker‐Hale, Natalya Beshko, Mariyo Boboev, Colin Clubbe, Davron Dekhkonov, Aibek Dolotbakov, Mehmet Firat, Thomas Freeth, Sjaak de Groot, Avni Hajdari, Georgy A. Lazkov, Ormon Sultangaziev, Komiljon S. Tojibaev, Ben J. M. Zonneveld, Kaiyrkul T. Shalpykov, Samuel F. Brockington   +17 more
wiley   +1 more source

Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40‐item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF‐specific minimal clinically important difference (MCID) has not been ...
Eugene Oh, Jessa E. Miller, Michelle J. Lee, Anna Zemke, David Baraghoshi, Matthew J. Strand, Jeremiah A. Alt, Todd E. Bodner, Michael Chang, Naweed I. Chowdhury, Patricia H. Eshaghian, Anne E. Getz, Jennifer L. Goralski, David A. Gudis, Peter H. Hwang, Ashoke Khanwalkar, Adam J. Kimple, Jivianne T. Lee, Douglas A. Li, Jess C. Mace, Jayakar V. Nayak, Jonathan B. Overdevest, Zara Patel, Daniella K. Safatian, Rodney J. Schlosser, Brent Senior, Amanda L. Stapleton, Timothy L. Smith, Zachary M. Soler, Jeffrey D. Suh, Grant A. Turner, Marilene B. Wang, Milene T. Saavedra, Jennifer L. Taylor‐Cousar, Daniel M. Beswick   +34 more
wiley   +1 more source

Factors Associated with 30-day Major Adverse Cardiovascular Event in Acute Coronary Syndrome Patients with Non-Dialysis Chronic Kidney Disease: A Retrospective Cohort Study

Acta Medica Indonesiana, 2023
Background: Acute coronary syndrome (ACS) accounts for the majority of ischemic heart disease-related deaths. It is known that ACS patients with chronic kidney disease (CKD) tend to have worse clinical outcomes, including major adverse coronary events ...
Eka Ginanjar, Ni Made Hustrini, Arif Mansjoer, M Shiddiq Al Hanif   +3 more
doaj  

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems

Arthritis &Rheumatology, EarlyView.
Objective Disease activity plays a central role in rheumatoid arthritis (RA) clinical studies. The inconsistent availability of data on disease activity in real‐world electronic health records (EHRs) data has limited the ability to generate real‐world evidence (RWE).
David Cheng, Xuan Wang, Gregory C. McDermott, Jennifer S. Hanberg, Zoe Love, Katherine Zhong, Mary Jeffway, Jue Hou, Vidul Panickan, Rahul Sangar, Ying Qi, Connor Melley, Lauren Costa, Dakota Feil, Rachael Matty, Dana Weisenfeld, Abisayo Animashaun, Aimee Schreiner, Sara Morini, Lauren Rusnak, Andrew Cagan, Misti Paudel, J. Michael Gaziano, Brian Sauer, Michael Weinblatt, Joshua Baker, Bryant England, Yuk‐Lam Ho, Kelly Cho, Paul Monach, Grant W. Cannon, Nancy Shadick, Ted R. Mikuls, Tianxi Cai, Katherine P. Liao   +34 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source